Coronavirus vaccine formulations
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
1. An immunogenic composition comprising:
(i) a nanoparticle comprising a coronavirus S (CoV S) glycoprotein having the amino acid sequence of SEQ ID NO: 87, and a non-ionic detergent core;
(ii) a pharmaceutically acceptable buffer, and
(iii) a saponin adjuvant.
2. The immunogenic composition of claim 1 , comprising between about 5 μg and about 25 μg of CoV S glycoprotein.
3. The immunogenic composition of claim 2 , comprising about 5 μg of CoV S glycoprotein.
4. The immunogenic composition of claim 1 , wherein the saponin adjuvant comprises at least two iscom particles, wherein:
the first iscom particle comprises fraction A of Quillaja saponaria Molina and not fraction C of Quillaja saponaria Molina; and
the second iscom particle comprises fraction C of Quillaja saponaria Molina and not fraction A of Quillaja saponaria Molina.
5. The immunogenic composition of claim 4 , wherein fraction A of Quillaja saponaria Molina accounts for 50-96% by weight and fraction C of Quillaja saponaria Molina accounts for the remainder, respectively, of the sum of the weights of fraction A of Quillaja saponaria Molina and fraction C of Quillaja saponaria Molina in the adjuvant.
6. The immunogenic composition of claim 4 , wherein fraction A of Quillaja saponaria Molina and fraction C of Quillaja saponaria Molina account for about 85% by weight and about 15% by weight, respectively, of the sum of the weights of fraction A of Quillaja saponaria Molina and fraction C of Quillaja saponaria Molina in the adjuvant.
7. The immunogenic composition of claim 1 , comprising about 50 μg of saponin adjuvant.
8. The immunogenic composition of claim 1 , wherein the non-ionic detergent core is selected from the group consisting of polysorbate-20 (PS20), polysorbate-40 (PS40), polysorbate-60 (PS60), polysorbate-65 (PS65), and polysorbate-80 (PS80).
9. A method of stimulating an immune response against SARS-CoV-2 in a subject comprising administering the immunogenic composition of claim 1 .
10. The method of claim 9 , comprising between about 5 μg and about 25 μg of CoV S glycoprotein.
11. The method of claim 10 , comprising 5 μg of CoV S glycoprotein.
12. The method of claim 9 , wherein the saponin adjuvant comprises at least two iscom particles, wherein:
the first iscom particle comprises fraction A of Quillaja saponaria Molina and not fraction C of Quillaja saponaria Molina; and
the second iscom particle comprises fraction C of Quillaja saponaria Molina and not fraction A of Quillaja saponaria Molina.
13. The method of claim 12 , wherein fraction A of Quillaja saponaria Molina accounts for 50-96% by weight and fraction C of Quillaja saponaria Molina accounts for the remainder, respectively, of the sum of the weights of fraction A of Quillaja saponaria Molina and fraction C of Quillaja saponaria Molina in the adjuvant.
14. The method of claim 12 , wherein fraction A of Quillaja saponaria Molina and fraction C of Quillaja saponaria Molina account for about 85% by weight and about 15% by weight, respectively, of the sum of the weights of fraction A of Quillaja saponaria Molina and fraction C of Quillaja saponaria Molina in the adjuvant.
15. The method of claim 9 , comprising about 50 μg of saponin adjuvant.
16. The method of claim 9 , wherein the non-ionic detergent core is selected from the group consisting of polysorbate-20 (PS20), polysorbate-40 (PS40), polysorbate-60 (PS60), polysorbate-65 (PS65), and polysorbate-80 (PS80).
17. The method of claim 9 , wherein the subject is administered a first dose at day 0 and a boost dose at day 21.
18. The method of claim 9 , wherein a single dose of the immunogenic composition is administered.
19. The method of claim 9 , comprising administering a second immunogenic composition different from the first immunogenic composition.
20. The method of claim 19 wherein the second immunogenic composition comprises an mRNA encoding a SARS-Cov-2 Spike glycoprotein, a plasmid DNA encoding a SARS-Cov-2 Spike glycoprotein, an viral vector encoding a SARS-Cov-2 Spike glycoprotein, or an inactivated SARS-CoV-2 virus.